BioLine RX Valuation
| BLRX Stock | ILS 1.50 0.10 6.25% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. BioLine RX shows a prevailing Real Value of S1.37 per share. The current price of the firm is S1.5. Our model approximates the value of BioLine RX from analyzing the firm fundamentals such as Current Valuation of (13.02 M), shares owned by insiders of 0.25 %, and Return On Equity of -0.37 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioLine RX's price fluctuation is dangerous at this time. Calculation of the real value of BioLine RX is based on 3 months time horizon. Increasing BioLine RX's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioLine RX is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLine Stock. However, BioLine RX's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.5 | Real 1.37 | Hype 1.5 |
The real value of BioLine Stock, also known as its intrinsic value, is the underlying worth of BioLine RX Company, which is reflected in its stock price. It is based on BioLine RX's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioLine RX's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioLine RX helps investors to forecast how BioLine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLine RX more accurately as focusing exclusively on BioLine RX's fundamentals will not take into account other important factors: About BioLine RX Valuation
The stock valuation mechanism determines BioLine RX's current worth on a weekly basis. Our valuation model uses a comparative analysis of BioLine RX. We calculate exposure to BioLine RX's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioLine RX's related companies.BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
8 Steps to conduct BioLine RX's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioLine RX's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioLine RX's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioLine RX's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioLine RX's revenue streams: Identify BioLine RX's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioLine RX's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioLine RX's growth potential: Evaluate BioLine RX's management, business model, and growth potential.
- Determine BioLine RX's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioLine RX's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |